OTC Markets · Biotechnology · USD

Aditxt, Inc. (ADTX) Stock Analysis

Aditxt, Inc. (ADTX) is a Biotechnology stock listed on OTC Markets and quoted in US Dollar.

Last Updated: October 20, 2026

ADTX

$0.001

$0.00 (0.00%)

Oct 20, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ADTX with… →

ADTX Key Statistics

As of Oct 20, 2026

Trading

Open: $0.001
Previous Close: $0.001
Volume: 2.02M

Valuation

Market Cap: $997.98K
P/S ratio: 69.61

Financials (FY)

Revenue (FY): $3.20K−97.62%
Net Income (FY): −$41.71M
Shares Outstanding: 997.98M
1-Year Return: −100.00%

Dividend and dates

Avg Volume: 19.47M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 20, 2026, ADTX closed at $0.001, −100.00% over 1 year.

Aditxt, Inc. (ADTX) has a market capitalization of $997.98K.

In fiscal 2025, ADTX reported revenue of $3.20K.

ADTX Stock Return by Calendar Year

Aditxt, Inc. (ADTX) return since Jan 2025: what $10,000 became

1 year: $10,000 $0.001; −99.99999%
Since Jan 2025: $10,000 $0.00001; −99.9999999%

If you had invested $10,000 in Aditxt, Inc. (ADTX) at the close on January 10, 2025, the earliest close on record here, it would have been worth $0.00001 at the close on October 20, 2026: −99.9999999% in total, −99.999% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	−100.00%
2025	−99.98%

As of October 20, 2026.

ADTX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$3.20K	−$41.71M	−1,305,608.8%
2024	$133.99K	−$34.45M	−25,709.2%
2023	$645.18K	−$32.38M	−5,018.9%
2022	$933.72K	−$27.65M	−2,961.3%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$3.20K	$268.00	−$19.57M	−$41.71M	−1,305,608.8%
2024	$133.99K	−$493.49K	−$27.86M	−$34.45M	−25,709.2%
2023	$645.18K	−$111.66K	−$26.06M	−$32.38M	−5,018.9%
2022	$933.72K	$166.94K	−$24.94M	−$27.65M	−2,961.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ADTX Valuation vs Biotechnology Median

Median of 608 stocks

Metric	ADTX	Biotechnology median	vs median
P/S ratio	69.61	13.30	5.2x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

Aditxt, Inc. (ADTX) is capitalised at $997.98K on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 26 employees.

The most recent close on file for ADTX is $0.001, dated October 20, 2026. The close was unchanged from the previous session.

Financial Health

Fiscal 2025 revenue came to $3.20K. That is −97.62% against the prior fiscal year, when revenue was $133.99K. The same year closed with a net loss of $41.71M.

Across the 4 fiscal years on file, revenue moves from $933.72K in 2022 to $3.20K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The price-to-sales ratio is 69.61. On price-to-sales that is 5.2 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Annualized volatility over the trailing 1 year is 428.81%. The trailing one-year total return is −100.00%. The stored price history starts on January 10, 2025, and the total return since then is −100.00%.

Growth & Income

The record shows no dividend for ADTX.

The record holds one complete calendar year, 2025, which returned −99.98%. 2026 is still running; the total return is −100.00% year to date.

Peer Comparison

Aditxt, Inc. (ADTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Aditxt, Inc.	ADTX	$997.98K	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 20, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Aditxt, Inc.

Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions. Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health. The company has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.

Visit website →